At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results CEO Yvonne Greenstreet ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Peripheral neuropathy damages peripheral nerves, causing numbness, tingling, and weakness, often starting in the feet and ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

The effectiveness of symptom improvement was also confirmed in the Phase 2b trial for chronic inflammatory demyelinating polyneuropathy (CIDP) that was disclosed together. Partner company Immunovant ...

A study published in July 2025 issue of BMC Neurology reported limited data on therapeutic plasma exchange (PE) and immunoadsorption (IA) in chronic inflammatory demyelinating polyneuropathy (CIDP), ...

Medically reviewed by Christopher Lee, MD Treatment for ATTR-CM has historically been symptom management. However, until 2019, the United States Food and Drug Administration (FDA) did not approve any ...

People with any type of substance use disorder (SUD) stand a 24% higher risk of having an unplanned hospital readmission within 30 days of a previous discharge compared with those without the disorder ...

Subclinical synovitis is significantly more common among patients with psoriasis without musculoskeletal involvement than ...

Among patients with T2D and DPN, some with nonpainful DPN developed neuropathic pain over a 5-year period while others with painful DPN experienced relief.